DYRK2 and lung adenocarcinoma: Conversely, DYRK2 was downregulated in lung adenocarcinoma and squamous cell carcinoma [135], diffuse large B-cell lymphoma [136], CRC [137], hepatocellular carcinoma (HCC) [138,139] and high-grade glioma [140].